The business’s revenue for the quarter was up 25.3% on a year-over-year basis.
Advertisement
“We have delivered results across all of our businesses that are on-track or ahead of company expectations for the quarter”, he said, “and today we are affirming our full year 2016 revenue and adjusted diluted EPS financial guidance while increasing investment in Branded and Generics [research and development] as well as Belbuca and Xiaflex promotion”.
When it comes to the Analysis of a Stock, Price Target plays a vital role.
Citi’s Liav Abraham says Endo’s relatively uneventful quarter alleviates some caution around the stock following three consecutive quarterly earnings of negative surprises. Deutsche Bank AG reissued a “buy” rating and set a $61.00 price objective (down from $65.00) on shares of Endo International PLC in a report on Monday, April 18th. Endo International plc was founded in 1920 and is headquartered in Dublin, and Ireland. These analysts have also projected a Low Estimate of $0.76/share and a High Estimate of $1.19/share. LS Investment Advisors LLC boosted its stake in Endo International PLC by 152.3% in the second quarter. Endo International plc (NASDAQ:ENDP) has a Return on Assets (ROA) of -8.2%. The share price is trading in a range of $17.75 – $18.43.
While looking at the Stock’s Performance, Endo International plc now shows a Weekly Performance of 27.27%, where Monthly Performance is 32.39%, Quarterly performance is 71.08%, 6 Months performance is -52.55% and yearly performance percentage is -72.38%. Vetr downgraded Endo International PLC from a “strong-buy” rating to a “buy” rating and set a $19.14 price target on the stock.in a research report on Thursday, July 7th. The total 978.16 thousand shares were bought and sold throughout the most recent trading session more than average volume of 706.75 thousand shares. The company has the institutional ownership of 98.90% while the Beta factor was 0.89. Volume of trade was was down over the average, with 7,644,545 shares of ENDP changing hands under the typical 8,776,020 shares. The most optimistic analyst sees the stock reaching $85 while the most conventional predicts the target price at $15.
But here’s where things get murky, Endo’s adjusted numbers of $192 million in net income and 86 cents EPS are actually lower than last year’s adjusted $204 million net and $1.08 per share.
Adjusted diluted EPS from ongoing operations of $0.86 contrast to second quarter 2015 adjusted diluted EPS from ongoing operations of $1.08. The company now has an average rating of “Hold” and a consensus price target of $39.78.
Advertisement
“During the second quarter 2016, Endo remained focused on operational execution”. The Company has a portfolio of branded pharmaceuticals that includes brands, such as Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel.
